Skip to main content
. Author manuscript; available in PMC: 2013 Mar 22.
Published in final edited form as: Vaccine. 2011 Jul 7;29(38):6485–6497. doi: 10.1016/j.vaccine.2011.06.088

Table 3.

Completed randomized trials of prostate cancer vaccines

Immunotherapy agent (trial) Endpoint # of patients Outcome Ref.
Sipuleucel-T (IMPACT) OS 512 Prolonged OS (25.8 vs. 21.7 months for placebo (P = 0.03), no change in time to progression (30)
Sipuleucel-T (D9901) TTP 127 Prolonged OS (25.9 vs. 21.4 months for placebo (P = 0.01), no change in time to progression (31)
PSA-TRICOM TTP 125 Prolonged OS (25.1 vs. 16.6 months for placebo (P = 0.0061), no change in time to progression (36)
GVAX (VITAL-1) OS 626 No difference in median OS (20.7 vs. 21.7 months, P = 0.78) (66)
GVAX (VITAL-2; prematurely terminated) OS 408 OS shorter in docetaxel/vaccine arm vs. docetaxel/prednisone arm (12.2 vs. 14.1 months, P = 0.0076) (65)